Publications by authors named "Nicholas S Roberts"
Early-life seizures can be refractory to conventional antiseizure medications (ASMs) and can also result in chronic epilepsy and long-term behavioral and cognitive deficits. Treatments targeting age-specific mechanisms contributing to epilepsy would be of clinical benefit. One such target is the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) subtype of excitatory glutamate receptor, which is upregulated in the developing brain.
View Article and Find Full Text PDFArticle Synopsis
- E2730 is a new anti-seizure medication that selectively inhibits the GABA transporter 1 (GAT1), showing promise in minimizing adverse effects compared to other ASMs.
- E2730 demonstrated effective anti-seizure properties in various animal models, with a significant margin between its therapeutic effects and motor incoordination side effects.
- The drug's mechanism involves enhancing GABA levels in certain conditions, indicating its potential for treating epilepsy with a lower risk of side effects.
Article Synopsis
- Injuries significantly impact global health, with the number of injury deaths rising from approximately 4.26 million in 1990 to about 4.48 million in 2017, despite a decline in age-standardized mortality rates.
- The Global Burden of Disease study measured both fatal and non-fatal injuries through years of life lost (YLLs) and years lived with disability (YLDs), which were combined into disability-adjusted life years (DALYs).
- While overall injury incidence increased, age-standardized DALYs decreased, indicating a need for ongoing research focused on injury prevention, better data collection, and improving access to medical care in high-burden areas.